Shoaib Ghias is a partner in the firm’s Business Law Department and a member of its Technology Companies & Life Sciences group. His representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, venture capital financings, mergers and acquisitions, public offerings, SEC reporting and compliance, and general corporate representation and counseling. His clients are in the life sciences, biotechnology, medical device, software and information technology services industries. Dr. Ghias joined Goodwin in 2013 and has worked with many of his company-side clients since their initial founding.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Private Company Financings, Joint Ventures and Strategic Matters

  • Tranquis Therapeutics, a biotechnology company focused on therapeutics for neurodegenerative and aging-related disease, in its $30 million Series A financing
  • C4 Therapeutics, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins, in its $73 million Series A financing and $170 million Series B financing
  • Relay Therapeutics, a biopharmaceutical company focusing on drug discovery centered on protein motion, in its $400 million Series C financing
  • Skyhawk Therapeutics, a biopharmaceutical company developing small molecule therapeutics that correct RNA expression, in its financings and corporate matters
  • Dragonfly Therapeutics, a biopharmaceutical company developing novel immunotherapies that harness the innate immune system to treat disease, in its financings and corporate matters
  • Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, in its joint venture with Overland Pharmaceuticals
  • Deerfield Catalyst, a medtech incubator committed to developing transformational solutions to improve patient outcomes and streamline care, in its formation and structuring maters
  • Moderna Therapeutics, a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines, in its corporate structuring matters

IPOs, Public Company Financings and deSPAC Transactions

  • C4 Therapeutics, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins, in its $182 million IPO and $180 million follow-on offering
  • The underwriters in the $84 million IPO of Rani Therapeutics, a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics
  • Better Therapeutics, a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in its business combination agreement with Mountain Crest Acquisition Corp II
  • Graphite Bio, a clinical-stage biotechnology company focused on therapies that harness targeted gene integration to treat or cure serious diseases, in its $273 million IPO
  • Eidos Therapeutics, a clinical-stage biopharmaceutical company focused on diseases caused by transthyretin (TTR) amyloidosis (ATTR), in its $122 million IPO, $100 million ATM facility, and $25 million strategic investment from Alexion
  • Zafgen, a biopharmaceutical company focusing on metabolic disorders, in its $102.7 million IPO, $129.5 million and $60 million follow-on offerings, and $50 million ATM facility
  • Viveve Medical, a medical device company focused on women’s intimate health, in its $32 million follow-on offering, $25 million and $6.7 million ATM facilities, $11.5 million stock and warrant offering, and $32 million debt-to-equity conversion
  • The underwriters in the $113 million IPO of Alarm.com, a cloud-based security and home automation company

Mergers and Acquisitions

  • AbCellera Biologics, a technology company with a centralized operating system for next-generation antibody discovery, in its acquisition of TetraGenetics
  • Zafgen, a biopharmaceutical company focusing on metabolic disorders, in its definitive merger agreement with Chondrial Therapeutics
  • Ocera Therapeutics, a biopharmaceutical company developing therapeutics for liver diseases, in its sale to Mallinckrodt for $42 million in cash and up to $75 million in contingent value rights for milestone payments
  • Albany Molecular Research Inc. (AMRI), a global CRMO, in its $358 million cross-border acquisition of Euticals
  • Purple Carrot, a vegan meal kit delivery company, in its cross-border sale to Oisix ra daichi for $12.8 million in cash and up to $17.2 million earn-out
  • NeuStar, a global information and analytics services provider, in its $2.9 billion sale to Golden Gate Capital and GIC
  • Millennial Media, a mobile ad platform company, in its approximately $250 million acquisition by AOL/Verizon, and its $108 million acquisition of Nexage, an online ad reseller
Professional Experience

Dr. Ghias holds a M.S. in Computer Science with a concentration in Bioinformatics. His master’s research was funded by the National Institute of Biomedical Imaging and Bioengineering and consisted of 3D image processing of PET and MRI data to guide neurosurgery at the Children’s Hospital of Michigan. He also holds a Ph.D. in Jurisprudence and Social Policy, focusing on comparative and international law and politics. His doctoral work has received awards or honorable mentions from the American Bar Foundation and the American Society of Comparative Law and the American Political Science Association.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

Ph.D., 2015
University of California, Berkeley
J.D., 2012
University of California, Berkeley
M.S., 2006
Wayne State University
B.S., 2003
Wayne State University

(magna cum laude, Phi Beta Kappa)

Admissions

Bar

Massachusetts
California
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师